Vir Biotechnology, Inc.
As of Oct 22, 2026, Vir Biotechnology is in Stage 2, the uptrend phase, now in week 9 (since Aug 21, 2026). It closed at $10.43, 11.5% below its 52-week high and above its 200-day average, which is rising.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is VIR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VIR among Biotechnology70th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …70 | VIR | Stage 2 · wk 9 | 91 | −6.0% |
Vir Biotechnology: quick answers
What stage is Vir Biotechnology in?
As of Oct 22, 2026, Vir Biotechnology (VIR) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 21, 2026 and is in week 9. What the four stages mean
Is Vir Biotechnology in an uptrend?
Yes. Vir Biotechnology is in a Stage 2 uptrend. It trades 11.4% above its 200-day average, which is rising.
How far is Vir Biotechnology from its 52-week high?
Vir Biotechnology closed at $10.43 on Oct 22, 2026, 11.5% below its 52-week high of $11.78. Its 52-week low is $5.12.
How has Vir Biotechnology performed over the past year?
As of Oct 22, 2026, Vir Biotechnology is up 66.3% over the past year and up 75.6% so far in 2026.
Which sector and industry is Vir Biotechnology in?
Vir Biotechnology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.